Latest Healthcare News

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.

Hexima Limited reported a stable cash balance of AUD 1.54 million for Q2 2025, with only minor net cash used in operating activities. The company remains focused on strategic opportunities to enhance shareholder value.

IMEXHS Limited reported steady Q2 FY25 revenue with an 11% rise in annual recurring revenue, supported by a $2.6 million capital raise and operational advances including a major Mexican contract win.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

InteliCare Holdings reported a $564,000 operating cash outflow in Q4 2025 and has secured $1 million in additional funding to support ongoing operations despite a cash runway under one quarter.